DE3486028T2 - Verabreichungsform von arzneimitteln. - Google Patents

Verabreichungsform von arzneimitteln.

Info

Publication number
DE3486028T2
DE3486028T2 DE8484401175T DE3486028T DE3486028T2 DE 3486028 T2 DE3486028 T2 DE 3486028T2 DE 8484401175 T DE8484401175 T DE 8484401175T DE 3486028 T DE3486028 T DE 3486028T DE 3486028 T2 DE3486028 T2 DE 3486028T2
Authority
DE
Germany
Prior art keywords
medicinal products
administrative form
administrative
medicinal
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8484401175T
Other languages
English (en)
Other versions
DE3486028D1 (de
Inventor
Martin C Carey
Alan C Moses
Jeffrey S Flier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/501,187 external-priority patent/US4548922A/en
Application filed by Individual filed Critical Individual
Publication of DE3486028D1 publication Critical patent/DE3486028D1/de
Application granted granted Critical
Publication of DE3486028T2 publication Critical patent/DE3486028T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
DE8484401175T 1983-06-06 1984-06-06 Verabreichungsform von arzneimitteln. Expired - Fee Related DE3486028T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/501,187 US4548922A (en) 1983-06-06 1983-06-06 Drug administration
US06/614,115 US4746508A (en) 1983-06-06 1984-05-25 Drug administration

Publications (2)

Publication Number Publication Date
DE3486028D1 DE3486028D1 (de) 1993-02-18
DE3486028T2 true DE3486028T2 (de) 1993-08-19

Family

ID=27053742

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484401175T Expired - Fee Related DE3486028T2 (de) 1983-06-06 1984-06-06 Verabreichungsform von arzneimitteln.

Country Status (7)

Country Link
US (1) US4746508A (de)
EP (1) EP0128831B1 (de)
AU (2) AU580262B2 (de)
CA (1) CA1228298A (de)
DE (1) DE3486028T2 (de)
DK (1) DK164203C (de)
IL (1) IL71967A (de)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910304A (en) * 1982-12-13 1999-06-08 Texas A&M University System Low-dose oral administration of interferons
US4959358A (en) * 1983-06-06 1990-09-25 Beth Israel Hospital Assn. Drug administration
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
US5045478A (en) * 1986-03-03 1991-09-03 Becton Dickinson And Company Vesicles and use thereof in an assay
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
GB8614189D0 (en) * 1986-06-11 1986-07-16 Leo Pharm Prod Ltd Pharmaceutical composition
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
ATE76311T1 (de) 1986-08-19 1992-06-15 Genentech Inc Einrichtung und dispersion zum intrapulmonalen eingeben von polypeptidwuchsstoffen und zytokinen.
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
DE3707987A1 (de) * 1987-03-12 1988-09-22 Behringwerke Ag Inaktivierung von human immunodeficiency virus (hiv) in proteinhaltigen loesungen durch phenole
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
CA1335076C (en) * 1987-04-01 1995-04-04 Hanna R. Kowarski Pharmaceutical composition and method for intranasal administration
US5807832A (en) * 1987-06-09 1998-09-15 Biotech Australia Pty Limited Oral delivery of biologically active substances bound to vitamin B12
JP2851627B2 (ja) * 1987-10-15 1999-01-27 シンテックス（ユー・エス・エイ）インコーポレイテッド 粉末形態ポリプペチド類の経鼻投与
FR2623715B1 (fr) * 1987-11-26 1990-12-21 Lafon Labor Structures peptidiques, immunogenes les contenant et leurs applications au controle de la fertilite
US5017371A (en) * 1988-01-06 1991-05-21 Amarillo Cell Culture Company, Incorporated Method for reducing side effects of cancer therapy
WO1989009225A1 (en) * 1988-03-28 1989-10-05 The Regents Of The University Of California Nerve growth factor peptides
HU206367B (en) * 1988-04-30 1992-10-28 Sandoz Ag Process for producing acid addition salts of steroid carboxylic acid-amidated taurine and glycine, as well as pharmaceutical compositions comprising such salts
US4937078A (en) * 1988-08-26 1990-06-26 Mezei Associates Limited Liposomal local anesthetic and analgesic products
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra
US5006343A (en) * 1988-12-29 1991-04-09 Benson Bradley J Pulmonary administration of pharmaceutically active substances
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
WO1990009800A1 (en) * 1989-02-21 1990-09-07 Washington University Modified forms of reproductive hormones
US5139023A (en) * 1989-06-02 1992-08-18 Theratech Inc. Apparatus and method for noninvasive blood glucose monitoring
WO1990015568A2 (en) * 1989-06-02 1990-12-27 Stanley Theodore H Apparatus and methods for noninvasive blood glucose monitoring
US6407061B1 (en) * 1989-12-05 2002-06-18 Chiron Corporation Method for administering insulin-like growth factor to the brain
US5624898A (en) * 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5585371A (en) * 1990-08-29 1996-12-17 Humanetics Corporation Treatment of immune system with Δ5-androstenes
IE921050A1 (en) * 1991-04-02 1992-10-07 Biotech Australia Pty Ltd Oral delivery systems for microparticles
EP0667783B1 (de) * 1991-11-07 1999-04-21 The University Of Southern California Zusammensetzungen und verfahren zur verhinderung der adhäsionbildung
GB2267435A (en) * 1992-06-01 1993-12-08 British Tech Group Factor VIII
IT1255449B (it) * 1992-06-30 1995-10-31 Fabio Berlati Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
US5364838A (en) * 1993-01-29 1994-11-15 Miris Medical Corporation Method of administration of insulin
RU2134693C1 (ru) * 1993-02-23 1999-08-20 Зе Трастис оф Принстон Юниверсити Способы формирования гликозидных связей, химическая композиция, гликозид и гликозидная библиотека
US5639866A (en) * 1993-02-23 1997-06-17 Princeton University Single-step formation of multiple glycosidic linkages
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
SE504074C2 (sv) * 1993-07-05 1996-11-04 Pharmacia Ab Proteinberedning för subkutan, intramuskulär eller intradermal administrering
US6737515B2 (en) 1993-11-19 2004-05-18 Washington University Follicle stimulating hormone-glycosylation analogs
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
CN1088580C (zh) 1994-12-22 2002-08-07 阿斯特拉公司 气溶胶药物制剂
EP0806945B1 (de) * 1994-12-22 2003-04-23 AstraZeneca AB Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
US5890489A (en) 1996-04-23 1999-04-06 Dermal Therapy (Barbados) Inc. Method for non-invasive determination of glucose in body fluids
US5804218A (en) * 1996-09-26 1998-09-08 Brigham & Women's Hospital, Inc. Methods and compositions for inhibiting enterohepatic cycling of bilirubin
US7135191B2 (en) * 1997-09-04 2006-11-14 Zsolt Istvan Hertelendy Urogenital or anorectal transmucosal vaccine delivery system
US6110489A (en) * 1998-05-01 2000-08-29 Cutler; Neal R. Use of quinolines and quinolones to treat male erectile dysfunction
US6132757A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6426084B1 (en) * 2000-06-19 2002-07-30 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US6194433B1 (en) 1998-10-05 2001-02-27 Neal R. Cutler Sexual dysfunction in females
US6187790B1 (en) 1999-03-04 2001-02-13 Neal R. Cutler Use of cilostazol for treatment of sexual dysfunction
US6132753A (en) * 1998-05-01 2000-10-17 Neal R. Cutler Treatment of sexual dysfunction in certain patient groups
US20030166525A1 (en) * 1998-07-23 2003-09-04 Hoffmann James Arthur FSH Formulation
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
JP2003501404A (ja) 1999-06-04 2003-01-14 デルルックス ファーマシューティカル コーポレイション 薬剤の脱水粒子からなる製剤およびこれの調製方法
US6303135B1 (en) 1999-07-08 2001-10-16 Neal R. Cutler Use of quinolines and quinolones to treat male erectile dysfunction
AU783208B2 (en) * 1999-12-09 2005-10-06 Novartis Vaccines And Diagnostics, Inc. Method for administering a cytokine to the central nervous system and the lymphatic system
WO2002070537A2 (en) * 2001-03-08 2002-09-12 Leo Pharma A/S Fusidic acid derivatives
US7041677B2 (en) * 2002-03-01 2006-05-09 R.T. Alamo Ventures I, Llc Use of monochloroflosequinan in the treatment of sexual dysfunction
AU2003225277A1 (en) * 2002-05-02 2003-11-17 Robert Harris Lipid removal from the body
US20040057983A1 (en) 2002-09-25 2004-03-25 David Schmidt Biomolecular wearable apparatus
US8999372B2 (en) * 2002-11-14 2015-04-07 Cure Pharmaceutical Corporation Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
US20040131662A1 (en) 2003-11-12 2004-07-08 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US20040191302A1 (en) 2003-03-28 2004-09-30 Davidson Robert S. Method and apparatus for minimizing heat, moisture, and shear damage to medicants and other compositions during incorporation of same with edible films
US9561182B2 (en) * 2003-08-22 2017-02-07 Cure Pharmaceutical Corporation Edible films for administration of medicaments to animals, methods for their manufacture and methods for their use for the treatment of animals
AU2004226666B9 (en) * 2003-04-02 2010-04-08 Ares Trading S.A. Liquid pharmaceutical formulations of FSH and LH together with a non-ionic surfactant
JP4871124B2 (ja) * 2003-06-20 2012-02-08 アレス トレーディング ソシエテ アノニム 凍結乾燥ｆｓｈ／ｌｈ製剤
US20070059346A1 (en) * 2003-07-01 2007-03-15 Todd Maibach Film comprising therapeutic agents
US20060024725A1 (en) 2004-07-30 2006-02-02 Robert Hussa Oncofetal fibronectin as a marker for pregnancy-related indications
US7523762B2 (en) * 2006-03-22 2009-04-28 Honeywell International Inc. Modulating gas valves and systems
EP2124883A2 (de) * 2006-12-12 2009-12-02 Amylin Pharmaceuticals, Inc. Pharmazeutische formulierungen und herstellungsverfahren dafür
WO2008098195A2 (en) * 2007-02-09 2008-08-14 Todd Maibach Film comprising nitroglycerin
US20090004254A1 (en) * 2007-06-19 2009-01-01 Todd Maibach Film comprising active drugs
US8602961B2 (en) 2008-05-15 2013-12-10 Lifewave Products Llc Apparatus and method of stimulating elevation of glutathione levels in a subject
WO2010065342A1 (en) 2008-11-25 2010-06-10 Temple University Angiocidin inhibition of tumor cell growth
PT2381923T (pt) 2008-12-22 2018-11-13 Serenity Pharmaceuticals Llc Administração intranasal de desmopressina
US20100286762A1 (en) * 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
KR20120042836A (ko) 2009-06-12 2012-05-03 아다지오 파마슈티컬즈 엘티디 설하 아포모르핀
KR101792696B1 (ko) 2009-06-18 2017-11-02 알레간 인코포레이티드 안전한 데스모프레신 투여
KR101890317B1 (ko) 2010-12-16 2018-08-22 선오비온 파마슈티컬스 인코포레이티드 설하 필름
US9789071B2 (en) 2012-06-27 2017-10-17 G2B Pharma, Inc. Intranasal formulation of epinephrine for the treatment of anaphylaxis
US9459201B2 (en) 2014-09-29 2016-10-04 Zyomed Corp. Systems and methods for noninvasive blood glucose and other analyte detection and measurement using collision computing
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
CA3019769C (en) 2015-04-21 2021-10-12 Sunovion Pharmaceuticals Inc. Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
US9554738B1 (en) 2016-03-30 2017-01-31 Zyomed Corp. Spectroscopic tomography systems and methods for noninvasive detection and measurement of analytes using collision computing
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
WO2021078999A1 (en) 2019-10-25 2021-04-29 Newmark Biotech, Llc Chewing gum or lozenge composition comprising cbd
US11617716B2 (en) 2021-06-10 2023-04-04 Belhaven BioPharma Inc. Dry powder formulations of epinephrine and associated methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1447489A (en) * 1972-10-06 1976-08-25 Leo Pharm Prod Ltd Fusidic acid conjugates
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
US4060606A (en) * 1975-06-25 1977-11-29 Leo Pharmaceutical Products Ltd. A/S 16-Ethers of fusidic acid derivatives
GB1527605A (en) * 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
IE44263B1 (en) * 1975-12-03 1981-09-23 Leo Pharm Prod Ltd New fusidic acid derivatives
GB1581335A (en) * 1976-07-05 1980-12-10 Leo Pharm Prod Ltd 16-s-acyl derivatives of fusidic acid
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration

Also Published As

Publication number Publication date
DK164203B (da) 1992-05-25
EP0128831A2 (de) 1984-12-19
EP0128831A3 (en) 1986-12-30
DK277084D0 (da) 1984-06-04
CA1228298A (en) 1987-10-20
AU580262B2 (en) 1989-01-12
AU3256189A (en) 1989-08-03
DK277084A (da) 1984-12-07
AU2902084A (en) 1984-12-13
EP0128831B1 (de) 1993-01-07
DE3486028D1 (de) 1993-02-18
IL71967A (en) 1989-09-10
DK164203C (da) 1992-10-19
US4746508A (en) 1988-05-24
IL71967A0 (en) 1984-09-30

Similar Documents

Publication Publication Date Title
DE3486028D1 (de) Verabreichungsform von arzneimitteln.
DK237884D0 (da) Farmaceutisk praeparat
FI844722L (fi) Med munstycke foersedd cigarrett.
DK266185A (da) Pasteuriseringsapparat
DE3886193D1 (de) Titan-Glimmermaterial.
ATA338184A (de) Regalfoerderzeug
ATE112172T1 (de) Targetformer von antitumor-methyltrithioagenzien.
DK336184D0 (da) Medikamentapplikator
DK58983D0 (da) Farmaceutisk praeparat
FI875167A (fi) Kallvalsad bandstaolprodukt.
FI844725L (fi) Med munstycke foersedd cigarrett.
FI853938A0 (fi) Anordning foer profilmaetning av raelshjul.
FI840092A0 (fi) Steriliserbara foliematerial foer primaerfoerpackningar av vattenhaltiga laekemedelsloesningar
FI882113A (fi) Foerfarande foer framstaellning av mekanisk massa.
DE3763519D1 (de) Heilnahrungsmittel.
DE3761048D1 (de) Umsetzungsprodukte von bis-glycidylthioethern.
DE3865090D1 (de) Verpackungstechnik von batterien.
DE241408T1 (de) Glimmerprodukt.
FI860597A (fi) Foerfarande foer framstaellning av en substituerad fenylurea.
DK233784D0 (da) Chokoladeprodukt
NO167513C (no) Fremstilling av 20-keto-delta 16-stereoider.
DE3480762D1 (de) Onkolytische arzneimittelkombinationen.
DK453785A (da) Laegemiddel med grf-virkning
DK376984D0 (da) Quininbaseret laegemiddel
DK639787A (da) Laegemiddelform indeholdende urapidil

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee